Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 1.00 |
| ▸ | FAAH | O00519 | 14/20 | 1.00 |
| ▸ | AADAC | P22760 | 1/20 | 0.80 |
| ▸ | RAF1 | P04049 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15612815 | 1.00 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL4256244 | 1.00 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL22223914 | 0.91 | EPHX2 (0.84) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL22223736 | 0.91 | EPHX2 (0.84) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL31114553 | 0.91 | EPHX2 (0.83) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL19358914 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL19358879 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL31114447 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL19358878 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL17420136 | 0.89 | EPHX2 (0.83) | EPHX2FAAHAADACRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | claimed |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-03-14 | — | — | US | claimed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | claimed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | claimed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | claimed |
| US-11564914-B2 | Methods of treating bone loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-31 | — | — | US | claimed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | claimed |
| US-20210378995-A1 | METHODS AND TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN MICROVASCULAR DYSFUNCTION | UNIVERSITE DE ROUEN NORMANDIE (FR) | 2021-12-09 | — | — | US | claimed |
| EP-3863639-A1 | METHODS AND TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN MICROVASCULAR DYSFUNCTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-08-18 | — | — | EP | claimed |
| US-20210228539-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2021-07-29 | — | — | US | claimed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | claimed |
| EP-2846825-B1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | UNIV CALIFORNIA (US) | 2021-05-05 | — | — | EP | claimed |
| CN-107132293-B | Novel method for rapidly detecting EETs of brain tissues | 南方医科大学 | 2020-12-15 | — | — | CN | claimed |
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | claimed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | claimed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | claimed |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-05 | — | — | US | claimed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12486222-B2 | Compounds as soluble epoxide hydrolase inhibitors | UNIVERSITAT DE BARCELONA (ES) | 2025-12-02 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250115548-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIV BARCELONA (ES) | 2025-04-10 | — | — | US | disclosed |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240182406-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2024-06-06 | — | — | US | disclosed |
| US-11987542-B2 | Co-crystal of sorafenib derivatives and process for preparation thereof | EICOSIS, LLC (US) | 2024-05-21 | — | — | US | disclosed |
| CN-118019728-A | Compounds as soluble epoxide hydrolase inhibitors | 巴塞罗那大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-03-14 | — | — | US | disclosed |
| EP-4313947-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Universitat de Barcelona (ES) | 2024-02-07 | — | — | EP | disclosed |
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | disclosed |
| CN-112638866-B | Co-crystals of sorafenib derivatives and process for preparing same | 艾科西斯有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11564914-B2 | Methods of treating bone loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2022200105-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2022-09-29 | — | — | WO | disclosed |
| EP-4063348-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Universitat de Barcelona (ES) | 2022-09-28 | — | — | EP | disclosed |
| US-11426385-B2 | Methods of improving cancer chemotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-20210378995-A1 | METHODS AND TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN MICROVASCULAR DYSFUNCTION | UNIVERSITE DE ROUEN NORMANDIE (FR) | 2021-12-09 | — | — | US | disclosed |
| US-11123311-B2 | Methods of treating mental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210228539-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2021-07-29 | — | — | US | disclosed |
| US-20210179549-A1 | CO-CRYSTAL OF SORAFENIB DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | EICOSIS, LLC | 2021-06-17 | — | — | US | disclosed |
| US-20210179549-A1 | CO-CRYSTAL OF SORAFENIB DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | EICOSIS, LLC | 2021-06-17 | — | — | US | disclosed |
| US-20210161881-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | CHIBA UNIVERSITY (JP) | 2021-06-03 | — | — | US | disclosed |
| US-20210155601-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-27 | — | — | US | disclosed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| EP-2846825-B1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | UNIV CALIFORNIA (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112638866-A | Co-crystal of sorafenib derivative and preparation method thereof | 艾科西斯有限责任公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-107132293-B | Novel method for rapidly detecting EETs of brain tissues | 南方医科大学 | 2020-12-15 | — | — | CN | disclosed |
| US-10858338-B2 | Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-08 | — | — | US | disclosed |
| US-10813894-B2 | Methods of inhibiting pain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200317813-A1 | TREATMENT AND DIAGNOSIS OF NON-PROLIFERATIVE DIABETIC RETINOPATHY | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | disclosed |
| US-20200197368-A1 | METHODS OF IMPROVING CANCER CHEMOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-06-25 | — | — | US | disclosed |
| US-10449182-B2 | Sorafenib derivatives as p21 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-22 | — | — | US | disclosed |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | disclosed |
| US-10369141-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3463470-A1 | TREATMENT AND DIAGNOSIS OF NON-PROLIFERATIVE DIABETIC RETINOPATHY | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2019-04-10 | — | — | EP | disclosed |
| US-20190077785-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-14 | — | — | US | disclosed |
| US-20190077785-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-14 | — | — | US | disclosed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | disclosed |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180125803-A1 | METHODS OF INHIBITING PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-10 | — | — | US | disclosed |
| WO-2017214394-A2 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017202957-A1 | TREATMENT AND DIAGNOSIS OF NON-PROLIFERATIVE DIABETIC RETINOPATHY | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017160861-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-2675274-B1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2675274-B1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160008342-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-01-14 | — | — | US | disclosed |
| US-9096532-B2 | Pyrazole inhibitors of COX-2 and sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150132408-A1 | SORAFENIB DERIVATIVES AS P21 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-05-14 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2846825-A1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | The Regents of The University of California (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2013138118-A1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (40 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182406-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, LTA4H | EPHX2 2/4885FAAH 5/4885AADAC 1922/4885 |
| US-20250115548-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, LTA4H | EPHX2 2/4885FAAH 5/4885AADAC 1922/4885 |
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | EPHX1, NCEH1, SOST | EPHX2 4/4885FAAH 61/4885AADAC 3264/4885 |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | EPHX1, ALDH1A2, EPHX2 | EPHX2 3/4885FAAH 30/4885AADAC 1919/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885FAAH 33/4885AADAC 717/4885 |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885FAAH 12/4885AADAC 2120/4885 |
| US-20210179549-A1 | CO-CRYSTAL OF SORAFENIB DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | EPHX1, VKORC1, VKORC1L1 | EPHX2 4/4885FAAH 233/4885AADAC 2116/4885 |
| US-20160008342-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885AADAC 873/4885 |
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | EPHX1, EPHX2, PTGER1 | EPHX2 2/4885FAAH 5/4885AADAC 3038/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885FAAH 13/4885AADAC 1463/4885 |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | EPHX1, FAH, EPHX2 | EPHX2 3/4885FAAH 84/4885AADAC 2104/4885 |
| US-20210161881-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | SNCA, PARK7, PYGB | EPHX2 3967/4885FAAH 2790/4885AADAC 1939/4885 |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885AADAC 873/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885FAAH 1/4885AADAC 871/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885FAAH 33/4885AADAC 717/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX2 10/4885FAAH 213/4885AADAC 2390/4885 |
| US-20180125803-A1 | METHODS OF INHIBITING PAIN | ATP2A3, ATP2A1, ATP2A2 | EPHX2 503/4885FAAH 40/4885AADAC 1577/4885 |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | SNCA, PARK7, PYGB | EPHX2 3967/4885FAAH 2790/4885AADAC 1939/4885 |
| US-11690837-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885AADAC 873/4885 |
| US-20150132408-A1 | SORAFENIB DERIVATIVES AS P21 INHIBITORS | TP53, CDKN1A, HCCS | EPHX2 2775/4885FAAH 4763/4885AADAC 2076/4885 |
| US-11987542-B2 | Co-crystal of sorafenib derivatives and process for preparation thereof | EPHX1, VKORC1, VKORC1L1 | EPHX2 4/4885FAAH 233/4885AADAC 2116/4885 |
| US-20200197368-A1 | METHODS OF IMPROVING CANCER CHEMOTHERAPY | ALOX5, EPHX1, ALOX12 | EPHX2 10/4885FAAH 23/4885AADAC 2060/4885 |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | EPHX2 3/4885FAAH 1/4885AADAC 253/4885 |
| US-20210155601-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | FAAH, FAAH2, EPHX2 | EPHX2 3/4885FAAH 1/4885AADAC 253/4885 |
| US-11564914-B2 | Methods of treating bone loss | EPHX1, NCEH1, SOST | EPHX2 4/4885FAAH 61/4885AADAC 3264/4885 |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | PTGES2, PTGS2, PTGES3 | EPHX2 5/4885FAAH 18/4885AADAC 251/4885 |
| US-10813894-B2 | Methods of inhibiting pain | ATP2A3, ATP2A1, ATP2A2 | EPHX2 503/4885FAAH 40/4885AADAC 1577/4885 |
| US-10449182-B2 | Sorafenib derivatives as p21 inhibitors | TP53, CDKN1A, HCCS | EPHX2 2775/4885FAAH 4763/4885AADAC 2076/4885 |
| US-12486222-B2 | Compounds as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, LTA4H | EPHX2 2/4885FAAH 5/4885AADAC 1922/4885 |
| US-10369141-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885AADAC 873/4885 |
| US-10858338-B2 | Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | EPHX2 3/4885FAAH 1/4885AADAC 253/4885 |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | TNF, PTGES2, IL2 | EPHX2 13/4885FAAH 16/4885AADAC 1640/4885 |
| US-11123311-B2 | Methods of treating mental disorders | FAAH, EPHX1, FAAH2 | EPHX2 4/4885FAAH 1/4885AADAC 871/4885 |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | GLS, REN, SLC5A2 | EPHX2 3353/4885FAAH 4685/4885AADAC 4383/4885 |
| US-20210228539-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | EPHX1, NCEH1, ALDH1A2 | EPHX2 4/4885FAAH 21/4885AADAC 1088/4885 |
| US-11426385-B2 | Methods of improving cancer chemotherapy | ALOX5, EPHX1, ALOX12 | EPHX2 10/4885FAAH 23/4885AADAC 2060/4885 |
| US-20190077785-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | FAAH, FAAH2, EPHX2 | EPHX2 3/4885FAAH 1/4885AADAC 253/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885FAAH 13/4885AADAC 1463/4885 |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885FAAH 1/4885AADAC 871/4885 |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | EPHX1, SERPINB1, PTGES | EPHX2 13/4885FAAH 11/4885AADAC 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.